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BACKGROUND: The aim of this study was to assess the relationship between serum lipoprotein (a) (Lp[a]) concentration and the 
requirement for peripheral artery disease (PAD) operations or incidence of major adverse cardiovascular events.
METHODS AND RESULTS: A total of 1472 people with PAD presenting with intermittent claudication (n=355), abdominal aortic 
aneurysm (n=989) or critical limb ischemia (n=128) were prospectively recruited from 4 outpatient clinics in Australia. Lp(a) 
was measured in serum samples collected at recruitment using an immunoassay. Participants were followed for a median 
(interquartile range) of 2.4 (0.1–6.1) years to record requirement for any PAD operation, defined to include any open or endo-
vascular PAD intervention (lower limb peripheral revascularization, abdominal aortic aneurysm repair, other aneurysm repair, 
or carotid artery revascularization). Myocardial infarctions, strokes, and deaths were also recorded. The association of Lp(a) 
with events was assessed using Cox proportional hazard analysis adjusting for traditional risk factors. Participants with Lp(a) 
≥30 mg/dL had a greater requirement for any PAD operation (hazard ratio, 1.20, 95% CI, 1.02–1.41) and lower limb peripheral 
revascularization alone (hazard ratio 1.33, 95% CI, 1.06–1.66) but no increased risk of major adverse cardiovascular events 
or all- cause mortality. Lp(a) ≥50 mg/dL and a 40 mg/dL increase in Lp(a) were also associated with an increased risk of lower 
limb peripheral revascularization alone but not with other outcomes.
CONCLUSIONS: In participants with PAD referred for hospital management those with high Lp(a) had greater requirement for 
lower limb peripheral revascularization but Lp(a) was not consistently associated with other clinical events.
Key Words: Peripheral artery disease ■ surgical treatment ■ lipoprotein (a)
Diseases of the abdominal aorta and its branches (peripheral artery disease; PAD), are a collection of chronic occlusive and aneurysmal diseases, 
commonly presenting as intermittent claudication, ab-
dominal aortic aneurysm (AAA) and critical limb is-
chemia.1–4 People with these PAD presentations have 
an incidence of major cardiovascular events (MACE; 
myocardial infarction, stroke or cardiovascular death) 
and requirement for arterial interventions, such as 
lower limb peripheral revascularization or AAA repair, 
of ≈20% and 30%, respectively, during short- term 
follow- up.5–10
Apolipoprotein B- containing lipoproteins, such 
as low- density lipoprotein- cholesterol (LDL- C), are 
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strongly implicated in cardiovascular disease.11 There 
is now a range of effective drugs for lowering LDL- C, 
such as statins and PCSK9 (proprotein convertase 
subtilisin/kexin type 9) inhibitors, which have been 
shown to substantially reduce MACE.8,12 Lipoprotein 
(a) (Lp [a]) is an LDL- like particle with a highly glyco-
sylated lipoprotein, called apolipoprotein (a), that has 
potent atherothrombotic and inflammatory proper-
ties.13 Circulating concentrations of Lp (a) are highly 
heritable and transmitted in families as a co- dominant 
trait.13 Population and case- control studies suggest 
that a high circulating concentration of Lp (a) is an 
important risk factor for the development of PAD.14–20 
The association of elevated circulating concentrations 
of Lp (a) with clinical events in people with established 
PAD has not been well studied. A smaller number of 
studies have investigated the association of eleva-
tion of Lp (a) with MACE21 and peripheral events22,23 
in people with established PAD. These studies have 
had a number of limitations, such as small sample 
sizes,22,23 studying populations of people presenting 
with PAD mixed with those presenting with other car-
diovascular diseases,21 not including the full spectrum 
of PAD presentations,21–23 and focusing on imaging 
outcomes such as patency22 rather than clinical end 
points.
Lp (a) is implicated in promoting atherosclerosis 
progression, thrombosis, and inflammation, which 
are all pathological processes thought to be critical in 
stimulating PAD progression and the need for surgi-
cal intervention.24 There is, therefore, a need to clarify 
the association of elevation in Lp (a) with requirement 
for peripheral artery operations and the incidence of 
MACE in a heterogeneous population of people with 
established PAD. The aims of the current study were 
to examine the associations of elevation in serum Lp (a) 
with requirement for peripheral artery operations and 
the incidence of MACE in a heterogeneous population 
of people with established PAD.
METHODS
Requests for access to data, analytic methods, and 
study materials should be made to the corresponding 
author.
Study Design and Participants
This investigation was designed as part of an ongo-
ing prospective cohort study that commenced in 2002 
and aimed to identify risk factors associated with the 
outcomes of people with PAD.25,26 Participants were 
recruited from outpatient vascular services in Australia, 
including The Townsville University Hospital, the Mater 
Hospital Townsville, Gosford Vascular Services and 
The Royal Brisbane and Women’s Hospital. The cur-
rent study included participants with intermittent clau-
dication, critical limb ischemia or an AAA diagnosed 
by a vascular specialist.27,28 Intermittent claudication 
was diagnosed in people with a history of leg pain 
on walking and absence of lower limb pulses, ankle- 
brachial index ≤0.9 or imaging evidence of a lower limb 
artery stenosis of ≥50% or occlusion.25,26 AAA was 
diagnosed if the orthogonal maximum outer to outer 
infra- renal aortic wall diameter was ≥30 mm measured 
from ultrasound or computed tomographic angiogra-
phy.25,26 Critical limb ischemia was diagnosed in peo-
ple with symptoms of rest pain, gangrene or arterial 
ulceration and evidence of limb ischemia.25,26 Written 
informed consent was obtained from all participants 
upon entry into the study. The study was performed in 
accordance with the Declaration of Helsinki and ethical 
approval was granted from institutional ethics commit-
tees (HREC/13/QTHS/125 and HREC/14/QTHS/203).
Blood Analyses
At recruitment, participants had a fasting blood test, 
to measure total cholesterol, triglyceride, LDL- C, 
CLINICAL PERSPECTIVE
What Is New?
• High serum lipoprotein (a) was associated with 
a small increased requirement for lower limb re-
vascularization but not consistently associated 
with other clinical events in people referred for 
management of peripheral artery disease.
What Are the Clinical Implications?
• More research is required to test whether lipo-
protein (a) lowering therapies are beneficial for 
people with established arterial disease, such 
as those with peripheral artery disease.
Nonstandard Abbreviations and Acronyms
Lp(a) lipoprotein (a)
PAD peripheral artery disease
MACE major adverse cardiovascular events
AAA abdominal aortic aneurysm
HR hazard ratio
LDL- C low- density lipoprotein- cholesterol
eGFR estimated glomerular filtration rate
CHD coronary heart disease
IQR interquartile range
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high- density lipoprotein- cholesterol, and C- reactive 
protein, as previously described.28,29 Serum was iso-
lated at recruitment and stored at −80°C until later 
batch analysis of Lp (a). Lp (a) was measured by an 
automated latex enhanced immunoassay (Quantia Lp 
(a) assay, Abbott Laboratories). Briefly, the Quantia Lp 
(a) assay is a turbidimetric immunoassay for the esti-
mation of Lp (a) in human serum in an Architect au-
toanalyzer C16000 (Abbott Diagnostics) and is based 
on the principle of an agglutination reaction.30,31 The 
interassay coefficient of variation for samples was 
<7%. Lp (a) measurement using this method has 
been significantly correlated with an liquid chroma-
tography–mass spectrometry method (n=50, r=0.972, 
P<0.001). The definition of elevated Lp (a) is contro-
versial with some guidelines considering ≥30  mg/dL 
abnormal32 but others proposing ≥50 mg/dL.33 In the 
current study ≥30 mg/dL was selected for the primary 
analysis since this threshold has been previously as-
sociated with increased clinical events in prior stud-
ies of other high- risk populations22,34 and also within 
meta- analyses.33 Sensitivity analyses were performed 
using other thresholds, including ≥50  mg/dl and a 
40 mg/dL (approximate standard deviation in the pop-
ulation) increase. Serum creatinine was measured as 
previously described26 and estimated glomerular filtra-
tion rate calculated using the Chronic Kidney Disease 
Epidemiology Collaboration formula.26
Definitions of Risk Factors and 
Medications Recorded
Smoking history was classified as current, former, 
or never smokers.25,35 Hypertension and diabetes 
Table 1. Comparison of Risk Factors in Participants With Different Presenting Problems
Risk Factor
Presenting Peripheral Artery Disease Problem
P Value
Intermittent Claudication 
(n=355) AAA (n=989)
Critical Limb Ischemia 
(n=128)
Age, y 66.4 (59.7–73.3) 74.0 (68.3–79.0) 68.7 (59.6–76.2) <0.001*
Men 265 (74.6%) 808 (81.7%) 81 (63.3%) <0.001*
Smoking <0.001*
Current 133 (37.5%) 286 (28.9%) 35 (27.3%)
Previous 182 (51.3%) 574 (58.0%) 60 (46.9%)
Never 40 (11.3%) 129 (13.0%) 33 (25.8%)
Hypertension 264 (74.4%) 765 (77.4%) 95 (74.2%) 0.439
Diabetes mellitus 120 (33.8%) 199 (20.1%) 63 (49.2%) <0.001*
Coronary heart disease 170 (47.9%) 507 (51.3%) 66 (51.6%) 0.533
Aspirin 258 (72.7%) 589 (59.6%) 84 (65.6%) <0.001*
Other anti- platelets 67 (18.9%) 195 (19.7%) 19 (14.8%) 0.415
Statin 257 (72.4%) 665 (67.2%) 83 (64.8%) 0.138
Fibrates 13 (3.7%) 29 (2.9%) 7 (5.5%) 0.297
Calcium channel blocker 105 (29.6%) 263 (26.6%) 39 (30.5%) 0.423
Beta- blockers 112 (31.5%) 374 (37.8%) 42 (32.8%) 0.081
Angiotensin converting enzyme inhibitor 141 (39.7%) 407 (41.2%) 61 (47.7%) 0.286
Angiotensin receptor blocker 86 (24.2%) 223 (22.5%) 32 (25.0%) 0.713
Metformin 82 (23.1%) 95 (9.6%) 40 (31.3%) <0.001*
Estimated glomerular filtration rate (mL/min per 
1.73 m2)†
83.0 (64.8–94.0) 68.0 (52.0–83.0) 75.5 (58.3–92.0) <0.001*
Total cholesterol‡ 4.40 (3.60–5.30) 4.30 (3.60–5.10) 4.00 (3.40–4.75) 0.001*
Triglyceride 1.60 (1.10–2.30) 1.40 (1.10–2.00) 1.35 (1.00–2.00) 0.086
Low- density lipoprotein† 2.30 (1.70–3.10) 2.30 (1.80–3.00) 1.95 (1.60–2.60) <0.001*
High- density lipoprotein‡ 1.20 (1.00–1.48) 1.14 (0.95–1.40) 1.20 (0.95–1.50) 0.126
C- reactive protein (mg/L)§ 3.0 (1.0–5.0) 3.0 (1.9–6.0) 5.0 (2.2–10.0) <0.001*
Lipoprotein (a) (mg/dL) 18.7 (7.4–52.9) 18.3 (9.4–55.2) 15.5 (5.8–40.8) 0.067
Lipoprotein (a) levels 0.261
<30 mg/dL 221 (62.3%) 632 (63.9%) 90 (70.3%)
≥30 mg/dL 134 (37.7%) 357 (36.1%) 38 (29.7%)
Shown are numbers (%) or medians and interquartile ranges. Lipids were reported in mmol/L. AAA indicates abdominal aortic aneurysm.
*P<0.01. Missing in †8, ‡1, and §36.
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mellitus were defined by a past history of diagnosis 
or treatment for these conditions.25,35 Coronary heart 
disease (CHD) was defined as a history of myocardial 
infarction, angina, or previous treatment for CHD.35 All 
prescribed medications including antiplatelet agents, 
statins, angiotensin- converting enzyme inhibitors, an-
giotensin receptor blockers, beta- blockers, and met-
formin were recorded at the time of recruitment.
Definition and Assessment of 
Cardiovascular and Peripheral Vascular 
Outcomes
Participants were followed up as part of normal care. 
Outpatient follow- up was performed according to local 
clinical practice. Participants were offered at least an-
nual follow- up. Outcome data were recorded during 
clinical reviews on prospectively defined case report 
forms. Hospital charts and electronic records were 
also reviewed by a vascular specialist. Outcome data 
were also obtained from linked hospital admission 
records as previously described.25,26,36,37 Linked data 
were obtained from the Queensland Hospital admit-
ted patient data collection which is regularly audited 
to minimize inaccuracies.38 PAD operations recorded 
included lower limb (open and endovascular) periph-
eral revascularization, carotid artery revascularization, 
open and endovascular AAA repair, and other aneu-
rysm repair.6,10,36 The primary outcome was require-
ment for any PAD operation, defined as including any 
of the peripheral artery interventions listed above. 
Secondary outcomes were MACE, lower limb (open or 
endovascular) peripheral revascularization, and AAA 
(open or endovascular) repair. The tertiary outcome 
was all- cause mortality. MACE was defined as the first 
occurrence of a major cardiovascular event including 
myocardial infarction, stroke, or cardiovascular death. 
Decisions about requirement for operative interven-
tions were at the discretion of the treating consult-
ant surgeon but were in line with current international 
guidelines,39,40 including lifestyle limiting intermittent 
claudication failing to respond to conservative therapy, 
Table 2. Comparison of Risk Factors in Participants With Different Serum Lipoprotein (a) Concentrations
Risk Factor
Serum Lipoprotein Concentration (mg/dL)
P Value<30 (n=943) ≥30 (n=529)
Age 72.0 (66.2–77.4) 71.3 (65.0–78.1) 0.451
Men 737 (78.2%) 417 (78.8%) 0.763
Smoking 0.163
Current 275 (29.2%) 179 (33.8%)
Previous 533 (56.5%) 283 (53.5%)
Never 135 (14.3%) 67 (12.7%)
Hypertension 708 (75.1%) 416 (78.6%) 0.123
Diabetes mellitus 234 (24.8%) 148 (28.0%) 0.184
Coronary heart disease 464 (49.2%) 279 (52.7%) 0.193
Aspirin 583 (61.8%) 348 (65.8%) 0.130
Other anti- platelets 172 (18.2%) 109 (20.6%) 0.268
Statin 621 (65.9%) 384 (72.6%) 0.008*
Fibrates
Calcium channel blocker 248 (26.3%) 159 (30.1%) 0.122
Beta- blockers 339 (35.9%) 189 (35.7%) 0.932
Angiotensin- converting enzyme 
inhibitor
386 (40.9%) 223 (42.2%) 0.648
Angiotensin receptor blocker 225 (23.9%) 116 (21.9%) 0.399
Metformin 145 (15.4%) 72 (13.6%) 0.359
Estimated glomerular filtration rate (mL/
min per 1.73 m2)†
71.0 (56.0–86.0) 73.0 (54.0–88.0) 0.277
Total cholesterol‡ 4.25 (3.50–5.00) 4.40 (3.70–5.10) 0.009*
Triglyceride 1.50 (1.10–2.10) 1.40 (1.00–2.10) 0.157
Low- density lipoprotein† 2.20 (1.70–3.00) 2.40 (1.90–3.10) 0.004*
High- density lipoprotein‡ 1.14 (0.95–1.40) 1.20 (1.00–1.46) 0.088
C- reactive protein (mg/L)§ 3.0 (1.9–6.0) 3.00 (1.9–6.2) 0.938
Shown are numbers (%) or medians and interquartile ranges. Lipids were reported in mmol/L.
*P<0.01. Missing in †8, ‡1, and §36.
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symptomatic or large asymptomatic AAA, and critical 
limb ischemia.10,41
Sample Size
We aimed to have adequate power to test our hy-
pothesis that Lp (a) ≥30 mg/dL was associated with a 
greater requirement for any PAD operation. Our prior 
studies suggest that PAD operations are common in 
people with established PAD occurring in between 
30% and 40% during short- term follow- up.6,10,36 
Monte- Carlo simulations suggest that a multivariable 
regression model is powered sufficiently when 10 
outcome events per degree of freedom of the predic-
tor variables are observed.42 We estimated that the 
2- year requirement for any PAD operation would be 
≈30% and planned to adjust for 10 variables, some 
with multiple degrees of freedom, including age, sex, 
smoking (current, former or never smokers), presen-
tation (intermittent claudication, AAA, or critical limb 
ischemia), diabetes mellitus, hypertension, CHD, statin 
prescription, LDL- C, and estimated glomerular filtra-
tion rate in the regression models. Based on these es-
timates we felt that a sample size of >1000 participants 
would be well powered to test the main hypothesis.
Data Analysis
Data were analyzed using the SPSS v 25 (IBM, 
Armonk, NY) software package. Continuous data 
that were not normally distributed, as confirmed 
using the Shapiro–Wilk test, and were presented as 
median and interquartile range. Between- group com-
parisons were conducted using the Mann–Whitney U 
and Kruskal–Wallis tests. Categorical variables were 
compared using Pearson Chi squared test. Kaplan–
Meier analysis was used to calculate the observed 
incidence of PAD operations and MACE and log- rank 
test performed to statistically compare incidence 
rates. For these analyses P<0.05 were considered 
significant. Cox proportional hazard analyses as-
sessed the association of serum Lp (a) ≥30  mg/dL 
with events adjusted for other risk factors. Analyses 
were adjusted for age, sex, smoking (current, former, 
or never smokers), presenting problem (intermittent 
claudication, AAA, or critical limb ischemia), diabetes 
mellitus, hypertension, CHD, statin prescription, LDL- 
C, and estimated glomerular filtration rate. Sensitivity 
analyses examined the association of events with Lp 
(a) ≥50  mg/dL and Lp (a) as a continuous variable 
using a 40  mg/dL increase (approximate SD in the 
cohort). For Cox regression analyses, Lp (a) was con-
sidered associated with the event concerned when 
the 95% CI of the hazard ratio did not cross one. The 
effect of age on the association of Lp (a) ≥30 mg/dL 
with events was also examined. For these analyses, 
participants were divided into those aged <72 and 
≥72  years (approximate median age of the cohort). 
The full Cox regression models are available from the 
corresponding author.
RESULTS
Participants and Outcomes
Between March 2002 and March 2018, 1472 people 
with intermittent claudication (n=355), AAA (n=989) 
Figure 1. Freedom from requirement for any peripheral artery disease operation in people referred 
for management of peripheral artery disease in relation to serum lipoprotein (a) ≥30 mg/dL. 
PAD indicates peripheral artery disease.
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and critical limb ischemia (n=128) were recruited. 
Participants’ age and sex, history of smoking and dia-
betes mellitus, and prescription of aspirin and met-
formin varied significantly according to the presenting 
problem (Table 1). Serum concentrations of total cho-
lesterol, LDL- C, and C- reactive protein, and estimated 
glomerular filtration rate also varied significantly be-
tween participants with different presenting problems 
(Table 1). Participants were followed for a median (in-
terquartile range) of 2.4 (0.1–6.1) years. During that time 
participants required a total of 1084 PAD operations, 
including 672 lower limb peripheral revascularizations, 
353 AAA repairs, 31 carotid artery revascularizations, 
and 28 repairs of other aneurysms. The participants 
also had a total of 230 myocardial infarctions and 75 
strokes. There were a total of 368 deaths of which 242 
were attributed to cardiovascular disease.
Association of High Serum Lp (a) With 
Risk Factors
At recruitment, 943 (64.1%) and 529 (35.9%) par-
ticipants had Lp (a) < and ≥30 mg/dL, respectively. 
Three hundred and eighty- nine (26.4%) and 154 
(10.5%) participants had Lp (a) ≥50 and ≥100  mg/
dL, respectively. As previously reported in other co-
horts,43,44 participants with Lp (a) ≥30  mg/dL were 
significantly more likely to be prescribed statins than 
those with lower Lp (a) levels (Table 2). Participants 
with Lp (a) ≥30  mg/dL also had significantly higher 
serum total cholesterol and LDL- C than those with 
lower Lp (a) levels (Table 2).
Association of High Serum Lp (a) With 
First Occurrence of Clinical Events
According to Kaplan Meier analyses, the require-
ments for the following procedures over 3 years 
were: any PAD operation 51.2% and 56.3% (P=0.041 
by log rank test; Figure 1), lower limb peripheral re-
vascularization 25.3% and 30.4% (P=0.029 by log 
rank test; Figure 2), and AAA repair 27.1% and 28.7% 
(P=0.282 by log rank test; Figure  3) in participants 
with Lp (a) < and ≥30  mg/dL, respectively. The in-
cidences of MACE were 17.7% and 19.7% (P=0.250 
by log- rank test; Figure  4) and all- cause mortality 
were 15.3% and 13.0% (P=0.885 by log- rank test; 
Figure 5) in participants with Lp (a) < and ≥30 mg/
dL, respectively. After adjustment for other risk fac-
tors, Lp (a) ≥30 mg/dL was associated with greater 
incidence of any PAD operation and lower limb pe-
ripheral revascularization alone but not AAA repair 
(Table 3 and Table S1). The incidence of MACE and 
all- cause mortality were not associated with Lp (a) 
≥30 mg/dL (Table 3).
Association of High Serum Lp (a) With 
Total Occurrence of Each Clinical Event
Of the 640 participants who had any PAD operation, 
422 had 1 operation and 218 had multiple operations 
(122 participants had 2, 41 had 3, 28 had 4, 11 had 5, 
4 had 6, 5 had 7, 3 had 8, 1 had 9, 1 had 10, 1 had 11, 
and 1 had 15). The total numbers of clinical events in 
participants with Lp (a) <30 and ≥30 mg/dL are shown 
in Table 4.
Figure 2. Freedom from requirement for lower limb peripheral revascularization in people referred 
for management of peripheral artery disease in relationship to serum lipoprotein (a) ≥30 mg/dL.
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Sensitivity Analyses
After adjustment for other risk factors, Lp (a) 
≥50 mg/dL or a 40 mg/dL increase in Lp (a) were 
associated with a greater requirement for lower 
limb peripheral revascularization but not with 
other events (Tables 3 and 5). In participants aged 
<72 years, Lp (a) ≥30 mg/dL was associated with 
a greater requirement for any PAD operation but 
not with other events (Table 6). In participants aged 
≥72 years, Lp (a) ≥30 mg/dL was associated with 
a greater requirement for lower limb peripheral re-
vascularization and all- cause mortality but not with 
other events (Table 6).
DISCUSSION
The main finding of this study was that participants with 
high serum Lp (a) were more likely to require lower limb 
peripheral revascularization. This finding was consist-
ent in analyses using different definitions of high Lp 
(a) but not present in a sensitivity analysis limited to 
younger participants. High Lp (a) was not consistently 
associated with other clinical events including the inci-
dence of MACE and mortality.
The rate of major cardiovascular events has been re-
ported to be higher in people with PAD than those pre-
senting with other cardiovascular diseases.8 The cohort 
Figure  3. Freedom from requirement for abdominal aortic aneurysm 
repair in people referred for management of peripheral artery disease in 
relationship to serum lipoprotein (a) ≥30 mg/d.
AAA indicates abdominal aortic aneurysm.
Figure  4. Freedom from major adverse cardiovascular events in people referred for 
management of peripheral artery disease in relationship to serum lipoprotein (a) ≥30 mg/dL.
MACE indicates major cardiovascular event (ie, myocardial infarction, stroke, or cardiovascular 
death).
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investigated in this study had a high rate of clinically im-
portant events. During a median follow- up of ≈2.5 years, 
about 40% of participants had at least 1 PAD operation 
and one quarter died. These event rates are higher than 
a number of recent reports from randomized trials al-
though these typically include highly selected people.7,8 
The participants included in the current study had a high 
frequency of cardiovascular risk factors, such as old age, 
critical limb ischemia, current smoking, diabetes melli-
tus, and CHD, which likely explains the high incidence 
of clinical events found. As has been previously reported 
in other studies, the prescription of best medical man-
agement was not optimal in the current cohort.45 About 
30% of participants were not prescribed statins for ex-
ample. This also likely contributed to the high incidence 
of events found. More effective methods are needed for 
implementation of best medical management in people 
with PAD.
Lp (a) has been suggested as a target for reduc-
ing clinical events using novel treatments to lower its 
circulating concentration.46–48 In the current study, 
high serum Lp (a) was consistently associated with 
a greater requirement for lower limb peripheral re-
vascularization. Participants with Lp (a) ≥30  mg/
mL, however, only had a 1.2- fold increased rate of 
lower limb peripheral revascularization. Also, the 
risk of lower limb peripheral revascularization was 
only mildly elevated in people with Lp (a) ≥50 mg/mL 
(hazard ratio 1.10). Furthermore, high Lp (a) was not 
associated with other events, such as the incidence 
of MACE. These findings differ from those reported 
from other cohorts.21,49 A study of a mixed cohort of 
Figure 5. Survival in people referred for management of peripheral artery disease in relationship to 
serum lipoprotein (a) ≥30 mg/dL.
Table 3. Association of Lipoprotein (a) ≥30 or ≥50 mg/mL With Clinical Events in People With PAD
Event Type or Model
Serum Lipoprotein Concentration (mg/mL)
≥30 mg/mL ≥50 mg/mL
Hazard model Unadjusted Adjusted Unadjusted Adjusted
Any PAD operation 1.18 (1.01–1.38) 1.20 (1.02–1.41) 1.08 (0.91–1.29) 1.10 (0.92–1.31)
Lower limb peripheral 
revascularization
1.27 (1.02–1.58) 1.33 (1.06–1.66) 1.17 (0.92–1.47) 1.29 (1.00–1.65)
AAA repair 1.13 (0.91–1.41) 1.14 (0.92–1.43) 1.15 (0.91–1.45) 1.06 (0.83–1.34)
MACE 1.14 (0.91–1.41) 1.16 (0.93–1.45) 1.06 (0.84–1.35) 1.12 (0.88–1.43)
All- cause mortality 1.02 (0.82–1.26) 1.08 (0.87–1.35) 1.04 (0.82–1.32) 1.15 (0.90–1.47)
Shown are hazard ratios and 95% CIs for models that were unadjusted or adjusted for age, sex, smoking history, diabetes mellitus, hypertension, coronary 
heart disease, presenting problem, statin prescription, low- density lipoprotein- cholesterol, and estimated glomerular filtration rate. Adjusted analyses did not 
include 16 participants because of missing low- density lipoprotein- cholesterol or estimated glomerular filtration rate results. AAA indicates abdominal aortic 
aneurysm; MACE, major cardiovascular events; and PAD, peripheral arterial disease.
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1503 people with coronary, cerebrovascular, or PAD 
reported that those with Lp (a) ≥50 mg/mL had haz-
ard ratios of 19.5 (95% CI, 10.5–36.1) and 54.5 (95% 
CI, 25.4–116.7) for myocardial infarction and ischemic 
stroke, respectively.21 The disparate findings of the 
current study could relate to the characteristics of the 
participants involved, such as their high- risk profile, 
high incidence of clinical events, and the inclusion 
of people with unique presentations, such as critical 
limb ischemia. Further studies are needed in similar 
PAD populations to clarify the importance of high Lp 
(a) as a risk factor for clinical events. Overall, how-
ever, the findings of the current study do not make 
a strong case for novel therapies to lower Lp (a) in 
people with PAD.
The current study has a number of strengths 
and weaknesses. A large heterogeneous population 
of people with PAD was included meaning findings 
are most relevant to similar populations. Information 
about a large range of vascular interventions was 
collected allowing detailed analysis of predictors of 
PAD operations. Analyses were adjusted for a large 
Table 4. Total Numbers of Peripheral Artery Disease Operations and Cardiovascular Events in Participants With Different 
Serum Lipoprotein (a) Concentrations
Event or Follow- Up
Lipoprotein (mg/dL)
<30 (n=943) ≥30 (n=529)
Follow- up, y 2.3 (0.1–6.2) 2.6 (0.1–5.6)
All- cause mortality 242 (25.7%) 126 (23.8%)
Cardiovascular death 156 (16.5%) 86 (16.3%)
Total myocardial infarction events 137 93
Number of participants who the myocardial 
infarction events occurred in
86 (9.1%) 54 (10.2%)
Total stroke events 47 28
Number of participants who the stroke events 
occurred in
39 (4.1%) 24 (4.5%)
Total of any peripheral artery disease operations 64 436
Number of participants who the peripheral artery 
disease operations occurred in
393 (41.7%) 247 (46.7%)
Total of lower limb revascularizations 392 280
Number of participants who the lower limb 
revascularizations occurred in
203 (21.5%) 137 (25.9%)
Total abdominal aortic aneurysm repairs 219 134
Number of participants who abdominal aortic 
aneurysm repairs occurred in
206 (21.8%) 130 (24.6%)
Shown are median (interquartile range) or numbers (%).
Table 5. Association of a 40 mg/dL Higher Lipoprotein (a) 
with Clinical Events in People With PAD
Event
Cox Proportional Hazard Model
Unadjusted Adjusted
Any PAD operation 1.04 (0.98–1.11) 1.05 (0.98–1.12)
Lower limb peripheral 
revascularization
1.09 (1.00–1.18) 1.11 (1.02–1.21)
AAA repair 1.06 (0.97–1.15) 1.04 (0.95–1.15)
MACE 1.00 (0.91–1.09) 1.02 (0.93–1.12)
All- cause mortality 0.97 (0.88–1.06) 1.00 (0.90–1.10)
Shown are hazard ratios and 95% CIs for models that are unadjusted 
or adjusted for age, sex, smoking history, diabetes mellitus, hypertension, 
coronary heart disease, presenting problem, statin prescription, low- density 
lipoprotein- cholesterol and estimated glomerular filtration rate. Adjusted 
analyses did not include 16 participants because of missing low- density 
lipoprotein- cholesterol, or estimated glomerular filtration rate results. AAA 
indicates abdominal aortic aneurysm; MACE, major cardiovascular events; 
and PAD, peripheral arterial disease.
Table 6. Association of Lipoprotein (a) ≥30 mg/mL With 
Clinical Events in People With PAD Aged <72 or ≥72 Years
Event
Age (y)
<72 ≥72
Any PAD operation 1.27 (1.03–1.58) 1.18 (0.91–1.53)
Lower limb peripheral 
revascularization
1.19 (0.89–1.58) 1.71 (1.15–2.55)
AAA repair 1.37 (0.99–1.89) 1.09 (0.79–1.50)
MACE 1.12 (0.80–1.57) 1.23 (0.90–1.67)
All- cause mortality 0.73 (0.50–1.06) 1.35 (1.01–1.80)
Shown are hazard ratios and 95% CIs for models that were adjusted for 
age, sex, smoking history, diabetes mellitus, hypertension, coronary heart 
disease, presenting problem, statin prescription, low- density lipoprotein- 
cholesterol and estimated glomerular filtration rate. Adjusted analyses did 
not include 16 participants because of missing low- density lipoprotein- 
cholesterol, or estimated glomerular filtration rate results. AAA indicates 
abdominal aortic aneurysm; MACE, major cardiovascular events; and PAD, 
peripheral artery disease.
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number of potential confounding factors. Sensitivity 
analyses were also performed. This study also has a 
number of limitations. It was an observational study 
and while high Lp (a) was not associated with a num-
ber of clinical events, such as MACE, this does not 
rule out a benefit of Lp (a) lowering. The findings of 
randomized trials are frequently disparate from those 
in observational studies. The current study involved 
a large number of analyses. While these analyses 
largely tested the same hypothesis (ie, that high 
serum Lp (a) was associated with an increased risk 
of clinical events), it needs to be recognized that such 
multiple testing introduces a risk of false discovery. 
Furthermore, despite including 1472 participants it is 
possible the study was underpowered to detect some 
of the associations that were tested particularly within 
the subgroups of younger and older participants. The 
distribution of Lp (a) concentrations did not include 
sufficiently large number of people with concentra-
tions >100 mg/dL to fully assess the associations of 
circulating Lp (a) concentrations. Finally, recruitment 
for the current study occurred over a prolonged pe-
riod from 2002 to 2018. This has a number of im-
plications. Firstly, medical management has varied 
substantial during this period, which may have impli-
cations for generalizing the results. Secondly, some 
of the samples were stored for a long period before 
analysis. Samples were stored at −80°C and thus we 
believe this had no impact on the findings, however 
this remains possible.
In conclusion, this study emphasizes the high in-
cidence of clinical events in people with PAD. High 
serum Lp (a) was associated with a greater require-
ment for lower limb peripheral revascularization but 
not consistently associated with other important clin-
ical events.
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Table S1. Fully adjusted Cox regression model for association of lipoprotein (a) ≥ 30 
mg/ml with requirement for any PAD operation. 
Risk factor Beta 
coefficient 
Standard 
error 
P value Hazard 
ratio 
Lower 
95% CI 
Upper 
95% CI 
Lipoprotein (a) 
≥30 
0.179 0.083 0.032 1.20 1.02 1.41 
Age (per year) -0.003 0.005 0.553 1.00 0.99 1.01 
Female sex -0.152 0.104 0.142 0.86 0.70 1.05 
Diabetes -0.101 0.096 0.294 0.90 0.75 1.09 
Hypertension 0.043 0.101 0.668 1.04 0.86 1.27 
Coronary heart 
disease 
-0.005 0.085 0.950 1.00 0.84 1.18 
Smoking 
history* 
  0.123    
Former 
smoking 
0.130 0.141 0.355 1.14 0.87 1.50 
Current 
smoking 
0.243 0.128 0.059 1.28 0.99 1.64 
Presenting 
problem† 
  <0.001    
 AAA 0.140 0.097 0.150 1.15 0.95 1.39 
 CLI 0.631 0.140 <0.001 1.88 1.43 2.48 
LDL-C (per 
mmol/l) 
-0.006 0.044 0.893 0.99 0.91 1.08 
eGFR (per 
ml/min/1.73m2) 
0.005 0.002 0.037 1.01 1.00 1.01 
Statin 
prescription 
-0.031 0.096 0.745 0.97 0.80 1.17 
 
AAA= abdominal aortic aneurysm; CLI= critical limb ischemia; LDL-C= low density 
lipoprotein-cholesterol; eGFR= estimated glomerular filtration rate; CI= confidence interval. 
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